Clinical significance of Kelch-like protein 11 antibodies

Estibaliz Maudes, MSc,* Jon Landa, MSc,* Amaia Muñoz-Lopetegi, MD, Thaís Armangue, MD, PhD, Mercedes Alba, Albert Saiz, MD, PhD, Francesc Graus, MD, PhD, Josep Dalmau, MD, PhD, and Lidia Sabater, PhD

Neurol Neuroimmunol Neuroinflamm 2020;7:e666. doi:10.1212/NXI.0000000000000666

Correspondence
Dr. Sabater
lisabate@clinic.cat

Abstract

Objective
To report the clinical and oncologic associations of antibodies against Kelch-like protein 11 (KLHL11-ab), recently suggested as biomarkers of a paraneoplastic brainstem cerebellar syndrome associated with testicular seminoma, and to determine the value of immunohistochemistry as a screening technique.

Methods
Studies included 432 sera or CSF from 329 patients with paraneoplastic (157) or autoimmune neurologic syndromes (172); 63 with neurologic symptoms and benign teratomas; 28 with small-cell lung cancer, and 12 healthy subjects. KLHL11-abs were examined using a cell-based assay (CBA) with HEK293 cells transfected with a human KLHL11 clone. The CBA specificity was confirmed by immunoprecipitation. All positive samples were examined by immunohistochemistry on rat brain sections.

Results
KLHL11-abs were detected in 32 patients by CBA, and patients’ antibodies immunoprecipitated KLHL11. Using rat brain immunohistochemistry, only 7 samples (22%) were positive. Patients’ median age was 28 years (range 9–76 years), and 16 (50%) were women. Tumors were identified in 23/32 (72%) patients, including 14 teratomas and 7 seminomas or mixed germ cell tumors. Thirteen (41%) patients had cerebellar ataxia (7) or encephalitis with brainstem cerebellar symptoms (6), 7 (22%) anti-NMDA receptor (NMDAR) encephalitis (5 with ovarian teratoma), 5 (16%) opsoclonus-myoclonus, 3 (9%) limbic encephalitis, and 4 (12%) diverse neurologic symptoms (3 with benign teratomas). Concurrent autoantibodies occurred in 14 (44%) patients (7 anti-NMDAR, 6 Ma2, and 1 Hu).

Conclusions
KLHL11-abs associate with a spectrum of syndromes and tumors wider than those previously reported; 44% of patients have concurrent neuronal antibodies, some of them (anti-NMDAR) pathogenically relevant. Brain immunostaining is not useful for routine screening of KLHL11-abs.

*These authors contributed equally to the manuscript.

From the Neuroimmunology Program (E.M., J.L., A.M.-L., T.A., M.A., A.S., F.G., J.D., L.S.), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, Universitat de Barcelona; Pediatric Neuroimmunology Unit (T.A.), Neurology Service, Sant Joan de Deu (SJD) Children’s Hospital. Barcelona; Service of Child and Adolescent Psychiatry (T.A.), Hospital Clinic, University of Barcelona; Unitat de Neuroimmunologia-Esclerosi Múltiple (A.S., J.D.), Servei de Neurologia, Hospital Clinic, Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Identification of new biomarkers of paraneoplastic neurologic syndromes (PNSs) is important because they assist in the diagnosis of the neurologic disease and guide the tumor search. Patients with Ma2 antibodies (Ma2-abs) develop a combination of limbic, diencephalic, and upper brainstem encephalitis that in young men associate with testicular cancer. Recently, Mandel-Brehm et al. reported a new autoantibody against Kelch-like protein 11 (KLHL11-ab) in 13 patients with paraneoplastic brainstem cerebellar encephalitis and testicular seminoma without Ma2-abs. Here, we determined the frequency of KLHL11-ab in a larger series of patients with PNS or with nonparaneoplastic autoimmune encephalitis. In addition, we assessed the value of routine brain immunohistochemistry to detect these antibodies.

Methods

Patients
We retrospectively assessed the presence of KLHL11-ab in 432 serum or CSF samples of 329 patients with PNS (157) or autoimmune neurologic syndromes (172), 63 with diverse neurologic symptoms in the setting of a benign teratoma (ovary or testicular), 28 with small-cell lung cancer (SCLC) without neurologic symptoms, and 12 healthy subjects. Among the 157 patients with definite or possible PNS, 121 had onconeural antibodies (61 Ma2, 40 Yo, and 20 Hu antibodies), and 36 had cancer without onconeural antibodies (17 SCLC, 8 bladder cancer, 6 testicular seminomas, 1 germ cell tumor of the thymus, 2 neuroblastomas, and 2 suspected ovarian and testicular cancer). The remaining 172 patients had autoimmune disorders: 78 anti-NMDA receptor (NMDAR) encephalitis (47 with ovarian teratoma), 38 MS, 35 neuromyelitis optica spectrum disorder (NMOSD), 14 opsoclonus-myoclonus, and 7 other autoimmune-related neurologic conditions.

Detection of KLHL11-ab by cell-based assay
Transfection of Myc-DDK-tagged KLHL11 human complementary DNA (#RC205228; Origene, Rockville, MD) in HEK293 cells was performed following standard procedures. Transfected cells were fixed with 4% paraformaldehyde (PFA) for 15 minutes, blocked with 10% goat serum with 0.1% Triton for 1 hour, and sequentially incubated with the patient’s sample (serum 1:10,000, CSF 1:1,000) and a commercial KLHL11-ab (1:1,000, #HPA054269; Sigma-Aldrich, St. Louis, MO) for 2 hours, and the corresponding secondary antibodies (1:1,000, anti-human Alexa488 #A-11013, anti-rabbit Alexa594 #A-11005; Thermo-Fisher Scientific, Waltham, MA) for 1 hour. Slides were mounted with Prolong gold antifade reagent (Thermo-Fisher Scientific), and images were taken with a Zeiss LSM710 microscope (Carl-Zeiss, Jena, Germany).

Brain immunostaining with peroxidase and fluorescence techniques
These studies were performed using reported techniques including biotin-avidin peroxidase on frozen sections of rat brain perfused with 2% PFA, followed by 4-hour postfixation with 2% PFA. Indirect immunofluorescence, to confirm the colocalization of human and commercial KLHL11-ab on the rat brain, was performed as in the cell-based assay (CBA) protocol described above.

Immunoprecipitation and Western blot assay
A lysate of HEK293 cells transfected with KLHL11 (total protein 500 μg) was incubated with serum samples (1:100) of patients with or without KLHL11-ab, for 1 hour at room temperature, precipitated with protein A/G (Thermo-Fisher Scientific), separated in an acrylamide gel (#NP03222; Thermo-Fisher Scientific), and transferred to nitrocellulose (#1704158; Bio-Rad, Hercules, CA). Strips were then incubated with the indicated commercial rabbit KLHL11-ab (1:1,000) overnight at 4°C, followed by a secondary anti-rabbit horseradish peroxidase (#NA934V; GE Healthcare, Chicago, IL) for 1 hour, and the reactivity developed with chemiluminescence.

Standard protocol approvals, registrations, and patient consents
The study was approved by the internal review board of Hospital Clinic (#HCB/2018/0192 protocol). Consent was obtained from all patients or proxies for the use serum and for research purposes.

Data availability
All data are reported within the article and available anonymously by request from qualified investigators.

Results
KLHL11-ab detection
KLHL11-ab were demonstrated in 32 patients by CBA (figure 1, A–F). CSF was available in 13 of 22 patients with KLHL11-ab in serum, and all CSF samples were also positive. To assure the specificity of the CBA, we selected KLHL11-ab–positive samples of 4 patients with different syndromes (cerebellar ataxia and seminoma, Ma2-ab–associated brainstem diencephalic encephalitis, and germ cell testicular tumor; opsoclonus-myoclonus with ovarian teratoma; and anti-NMDAR encephalitis with ovarian teratoma) for immunoprecipitation using KLHL11-expressing
HEK293 cells. Samples of patients containing KLHL11-abs but none of the controls (Ma2-ab-associated brainstem diencephalic encephalitis; 2 anti-NMDAR encephalitis, and a normal human serum), immunoprecipitated KLHL11 (figure 1G).

All 32 KLHL11-ab–positive samples were also examined using rat brain immunohistochemistry. Samples of 7 (22%) patients showed a robust reactivity with the cytoplasm of large neurons in the brainstem and deep cerebellar nuclei that colocalized with that produced by a commercial KLHL11-ab, confirming the specificity of patients’ KLHL11-abs (figure 2).

**Clinical profile of the 32 patients with KLHL11-abs**

Patients’ median age was 28.5 years (range 9–76 years), 16 (50%) were women, and 23 (72%) had a tumor (table). Benign teratomas were the most common associated tumors found in 14 (44%) patients (10 in the ovary and 4 in the testis). Seven (22%) patients had seminomas or mixed germ cell tumors (testicular 6 and thymus 1), 1 SCLC, and 1 ovarian cancer. Overall, 13 (41%) patients had cerebellar ataxia (7 patients) or cerebellar brainstem symptoms in the context of extensive encephalitis (6); 11 of these 13 patients had benign teratomas or germ cell tumors, and 5 harbored concurrent autoantibodies (4 Ma2 and 1 Hu). Seven (22%) patients had anti-NMDAR encephalitis, 5 of them with ovarian teratoma; 5 (16%) had opsoclonus-myoclonus, and 3 (9%) had limbic encephalitis, 2 of them with concomitant Ma2-abs. Four additional patients (12%) had heterogeneous neurologic symptoms, which in 3 associated with benign teratomas. Serum from patients with MS, NMOSD, SCLC without neurologic symptoms, and healthy controls were KLHL11-ab negative.

**Discussion**

The current findings show that the clinical and oncologic associations of KLHL11-abs are much wider than previously reported and that 44% of patients had concurrent neuronal antibodies, some of them (anti-NMDAR) pathogenically relevant.

As reported,⁵ we found a high frequency (72%) of tumors in patients with KLHL11-abs, but the majority were benign teratomas of the ovary or testis. This association cannot be explained by the selection of patients with anti-NMDAR encephalitis, as 50% of patients with ovarian teratomas and KLHL11-ab had other syndromes. Seminomas and mixed germ cell testicular tumors were the second most common tumor type, but, unlike the initial study,⁵ 57% of these patients had Ma2-abs. The fact that we examined a larger number of patients with Ma2-ab (61 vs 8) could explain this discrepancy.

Based on this and previous findings, KLHL11-abs can be identified in 3 clinical settings (table): (1) CNS syndromes with...
a predominant, but not exclusive, brainstem cerebellar involvement. KLHL11-abs (with or without Ma2-abs) frequently occur with tumors (benign teratoma or a testicular tumor) and associate with limited or moderate response to treatment (although one of our patients with a mixed germ cell tumor of the thymus and cerebellar ataxia had a notable improvement after steroids); (2) some patients with well-defined syndromes (anti-NMDAR encephalitis) have concurrent KLHL11-abs. In these cases, detection of KLHL11-abs does not change the clinical features or prognosis of classical anti-NMDAR encephalitis (e.g., 6 of 7 patients had substantial improvement [data not shown]); therefore, in this setting, detection of KLHL11-abs does not appear to have neurologic implications. The paradigm is similar to glial fibrillary acidic protein antibodies as accompaniments of anti-NMDAR encephalitis or NMOSD; and (3) about 5% (3 of 63) of the patients with neurologic syndromes that are not paraneoplastic or autoimmune may harbor KLHL11-abs associated with the presence of a teratoma.

<table>
<thead>
<tr>
<th>Neurologic syndrome (N)</th>
<th>Age (median [range])</th>
<th>Sex (F/M)</th>
<th>Tumors (N)</th>
<th>Other antibodies (N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-NMDAR encephalitis (7)</td>
<td>19 [13–29]</td>
<td>6/1</td>
<td>Ovarian teratoma (5)</td>
<td>Anti-NMDAR (7)</td>
</tr>
<tr>
<td>Cerebellar ataxia (7)</td>
<td>43 [15–57]</td>
<td>2/5</td>
<td>Seminoma (2)</td>
<td>Ovarian teratoma (2)</td>
</tr>
<tr>
<td>Brainstem diencephalic encephalitis (6)</td>
<td>37 [22–65]</td>
<td>0/6</td>
<td>Germ cell thymic tumor (1)*</td>
<td>Germ cell thymic tumor (2)</td>
</tr>
<tr>
<td>Opsoclonus-myoclonus (5)</td>
<td>37 [31–48]</td>
<td>5/0</td>
<td>Ovarian teratoma (1)</td>
<td>Ovarian teratoma (1)</td>
</tr>
<tr>
<td>Limbic encephalitis (3)</td>
<td>48 [12–76]</td>
<td>1/2</td>
<td>Testicular teratoma (1)</td>
<td>Testicular teratoma (1)</td>
</tr>
<tr>
<td>Chronic psychosis (2)</td>
<td>26, 19</td>
<td>F, M</td>
<td>Ovarian carcinoma (1)</td>
<td>Teratoma (2; ovarian, testicular)</td>
</tr>
<tr>
<td>Subacute encephalopathy* (1)</td>
<td>36</td>
<td>F</td>
<td>Ovarian teratoma (1)</td>
<td>Ovarian teratoma (1)</td>
</tr>
<tr>
<td>Extralimbic encephalitis* (1)</td>
<td>9</td>
<td>M</td>
<td>Ovarian teratoma (1)</td>
<td>Ovarian teratoma (1)</td>
</tr>
</tbody>
</table>

Abbreviations: NMDAR = NMDA receptor; SCLC = small-cell lung cancer.

* Previously reported.

* Subacute encephalopathy the setting of alcohol abuse.

* Cause unknown.

Table Clinical profile of patients with KLHL11-abs
KLHL11 is a protein member of the E3 ubiquitin ligase complex, and the intracellular location indicates that the antibodies cannot interfere with its function in vivo. Therefore, any immune mechanism related to KLHL11- abs and tumor or neurologic autoimmunity is likely T cell mediated.

A task for the future is to assess whether KLHL11 is frequently expressed by nonparaneoplastic tumors, particularly seminomas and mixed germinomas, and whether patients with these tumors without neurologic symptoms harbor these antibodies.

Acknowledgment
The authors thank Prof. Alexander Lossos, Department of Oncology and Neurology of the Hadassah-Hebrew University Medical Center, Jerusalem, Israel, and Dr. Joan Montaner, Service of Neurology, Hospital Vall d’Hebron, Barcelona, Spain, for providing complete clinical data of patients.

Study funding
This study was supported in part by Instituto Carlos III/ FEDER, Madrid (FIS 18/00067 [L. Sabater], FIS 17/00234, J. Dalmau; PIE 16/00014, J. Dalmau; CIBERER # CB15/00010, J. Dalmau); PERIS SLT006/17/00362, T. Armande); Mutua Madrileña Foundation Award (AP162572016, T. Armande); La Caixa Foundation Health Research, J. Dalmau; and Fundació CELLEX, J. Dalmau.

Disclosure
E. Maudes, J. Landa, and A. Munoz report no disclosures. T. Armandae received speaker honoraria from Bayer-Schering, Merck-Serono, Biogen Idec, Genzyme-Sanoﬁ, TEVA, Novartis, and Roche. F. Graus receives royalties from Euroimmun for the use of IgLON5 as an autoantibody test and honoraria for Assistant Editor of MedLink Neurology. J. Dalmau receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA as an autoantibody test. J. Dalmau received a licensing fee from Euroimmun for the use of GABAB receptor, GABAA receptor, DPPX, and IgLON5 as autoantibody tests. L. Sabater reports no disclosures. Go to Neurology.org/NN for full disclosures.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation November 7, 2019. Accepted in final form December 17, 2019.

Appendix

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jon Landa, MSc</td>
<td>IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Analyzed the data; immunohistochemical and immunoprecipitation studies; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Amaia Muñoz-Lopetegi, MD</td>
<td>Hospital Clínic and IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Analysis and interpretation of the data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Thaís Armande, MD, PhD</td>
<td>Hospital Clínic and IDIBAPS, Hospital Sant Joan de Deu, Barcelona, Spain</td>
<td>Author</td>
<td>Acquisition of clinical data and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Mercedes Alba</td>
<td>IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Immunohistochemical studies and revised the manuscript</td>
</tr>
<tr>
<td>Albert Saiz, MD, PhD</td>
<td>Hospital Clínic and IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Acquisition of clinical data; analysis and interpretation of the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Francesc Graus, MD, PhD</td>
<td>IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Acquisition of clinical data; analysis and interpretation of the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Josep Dalmau, MD, PhD</td>
<td>Hospital Clínic and IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Acquisition of clinical data; analysis and interpretation of the data; and revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Lidia Sabater, PhD</td>
<td>IDIBAPS, Barcelona, Spain</td>
<td>Author</td>
<td>Drafted the first version of the manuscript; analysis and interpretation of the data; and revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

References
Clinical significance of Kelch-like protein 11 antibodies
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000666

This information is current as of January 17, 2020